# Study to Evaluate Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients With Locally Advanced or Metastatic HR+/HER2- Breast Cancer

> **NCT04851613** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Laekna Limited** · enrollment: 256 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Afuresertib
- **DRUG:** Afuresertib/placebo

## Key facts

- **NCT ID:** NCT04851613
- **Lead sponsor:** Laekna Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-02-18
- **Primary completion:** 2026-10-30
- **Final completion:** 2026-12-30
- **Target enrollment:** 256 (ESTIMATED)
- **Last updated:** 2026-04-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04851613

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04851613, "Study to Evaluate Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients With Locally Advanced or Metastatic HR+/HER2- Breast Cancer". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT04851613. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*